). Its accuracy was proved to be excellent in a wide range of malignant cell concentrations. The method is demonstrated on three CML patients suffering from MRD after BMT. In conclusion, this method fulfills all criteria of competitive Q-RT-PCR. Because of its simplicity it is suitable for clinical laboratories and due to the high stability of the lysates used it may serve in the standardization of results between different laboratories.
Introduction
Chronic myeloid leukemia is a malignant disease characterized in almost 100% of cases by the presence of the BCR/ABL fusion gene in cells of the malignant clone. [1] [2] [3] The BCR/ABL gene results from the reciprocal chromosome translocation t(9;22)(q34,q11) karyotypically detected as Ph chromosome 4, 5 or from various complex translocations including chromosomes 9 and 22 with karyotypically undetected Ph chromosome. 6, 7 Two highly predominant types of fusion gene exist, depending on whether exon 2 or exon 3 of the major BCR region is fused to exon 2 of the ABL gene. 3, 8, 9 The BCR/ABL encodes a chimeric protein p210 considered to play a crucial role in leukemogenesis. 10, 11 Currently, the most efficient treatment for CML is bone marrow transplantation. The resulting effect is apparently achieved by the combination of the myeloablative preparative regimen and the alloimmune response of donor cells termed the graft-versus-leukemia (GVL) effect. 12 Although cure can be achieved in a high proportion of patients, disease relapse remains a major clinical problem. A sensitive method for detecting even very small numbers of leukemic cells is of crucial importance for the early detection of disease recovery and for commencement of the therapy at a time when the malignant clone is still small and the probability of therapeutic success is high. The most sensitive among all current methods is the two-step nested reverse transcription-polymerase chain reaction (RT-PCR), amplifying a cDNA segment of BCR/ABL fusion gene, which permits the detection of a single leukemic cell in 10 5 -10 6 normal cells. This sensitivity exceeds that of other methods by several orders of magnitude. In past years there have been papers published with conflicting opinions on the importance of PCR assay in the prediction of the disease evolution. 13, 14 However, the development of quantiative PCR completely dispelled all doubts. It is evident that qualitative PCR can confirm the presence of the BCR/ABL transcript in cells and thus identify patients after BMT belonging to a group with elevated risk of relapse, but has only a limited predictive value for disease evolution in individuals of this group. 15 By estimating the amount of BCR/ABL transcripts at regular time intervals, the quantitative PCR is able to monitor the proliferative activity of the malignant clone and thus unambiguously predict the relapse. [15] [16] [17] In general, several quantiative PCR strategies have been developed to estimate the amount of target molecules in a sample. The method including internal standardthe competitive PCR -checking for intratube variations and allowing easy, when some assumptions are fulfilled, absolute quantification, seems to be the most convenient for clinical laboratories. Two types of competitive RT-PCR assay for the BCR/ABL transcript amount estimations were recently worked up: the method using natural competitors from cell lines, 17, 18 and then the methods using artifically prepared competitors.
synthesis. Three exemplary cases of monitoring after BMT minimal residual disease are presented.
Materials and methods

Patient's sample processing
Thirty patients with CML after allogeneic BMT were tested by qualitative RT-PCR for more than a year at regular time intervals recommended by EICML Group. 20 Twenty-seven patients were from the Institute of Hematology and Blood Transfusion, Praha and three from the 2nd Department of Pediatrics of the 2nd Medical Faculty, Charles University, Praha. Eight of them became permanently positive and were monitored by quantitative RT-PCR. Fifty-two patients' samples were quantified.
Samples were obtained with the agreement of the Ethics Committee of the Institute of Hematology and Blood Transfusion (Praha, Czech Republic). Leukocytes were prepared from 10-20 ml of fresh peripheral blood in citrate anticoagulants by the method of red blood cell osmotic lysis. The cells were stored as 2 × 10 7 cell aliquots in liquid nitrogen or as 2 × 10 7 cell lysates in 1 ml GTC (4 M guanidinium thiocyanate, 25 mM sodium citrate pH 7, 0.5% sodium lauroylsarcosine, 0.72% 2-mercaptoethanol) 21 at −20°C for qualitative PCR. Cell lysates from 10 7 cells per ml GTC were prepared for the quantitative PCR assay.
RNA extraction
Total cellular RNA was prepared from 10 7 (for qualitative PCR) or from 5 × 10 6 (for quantitative PCR) cells by a slightly adapted method of Chomczynski and Sacchi. 21 The modification involved the following steps: (1) the aqueous phase mixed with isopropanol was kept at −20°C for 20 min; (2) after isopropanol precipitation the RNA pellet was washed twice with 75% cold ethanol followed each time by 10 min centrifugation at 10 000 g. Then, the RNA sediments from 10 7 cells or 5 × 10 6 cells were dissolved in 30 l of 15 l, respectively, of RNA quality water. DEPC (diethyl pyrocarbonate) was not used for water treatment because we often did not succeed in removing it completely which influenced the biological activity of samples. Deionised twice autoclaved water was therefore used. The quality of RNA was tested by electrophoresis on non-denaturing 1.5% agarose gel (Pharmacia, Uppsala, Sweden) and by RT-PCR of a control ABL gene using primers lying on a2 and a3 exons 22 ( Figure 1 ).
Reverse transcription
RNA was converted to cDNA and AMV (avian myeloblastosis virus) reverse transcriptase and random hexamer primers in a final reaction volume of 10 l. All reagents used were from Promega (Madison, WI, USA). Four microliters of total RNA (approximately 1-2 g of RNA) were added to the mixture of 1.45 l of RNA quality water, 2 l of AMV RT 5× buffer, 1 l of dNTP (10 mM), 0.5 l of dithiothreitol (100 mM), 0.2 l of random hexamer primers (250 M), 0.25 l of RNasin (20 U/l) and 0.6 l of AMV RTase (5-10 U/l). The reaction mixture was incubated at 42°C for 1 h, then cooled and either used for PCR or stored at −20°C. Neither denaturation of RNA before RT nor denaturation after RT were employed.
PCR assay
Two-step nested PCR assay with Taq polymerase was performed in a final volume of 25 l. The primers were synthesized by Genset (Paris, France), all other reagents were from Promega. The PCR products were detected by electrophoresis in a 2% agarose gel (Pharmacia) stained with ethidium bromide. Rigorous precautions were taken to prevent cross contaminations of samples. Negative and positive controls were used to assess cross contamination and sensitivity of the test. 16.85 l of water, 5 l of Taq polymerase 10× buffer, 0.5 l of dNTP (10 mM), 0.25 l of sense primer (50 M), 0.25 l of antisense primer (50 M) and 0.15 l of Taq polymerase (5 U/l) were mixed. The reaction mixture was covered by two droplets of mineral oil (Sigma, St Louis, MO, USA) and 2 l of cDNA were added underneath the oil. All preparation steps were performed on ice, the samples were placed into 95°C hot cycler (Quatro, Biosystems, Manchester, UK). The reaction was started with 3 min at 95°C, 2 min at 58°C and 2 min at 72°C, afterwards 35 cycles with 1 min at 94°C, 1.5 min at 57°C, 1.5 min at 72°C were performed and the reaction was completed by a final 7 min extension step at 72°C.
The first PCR
The second PCR
The performance of the second PCR differed from the first PCR only by using internal primers and 2 l of 100-fold diluted products of the first PCR instead of 2 l of cDNA. Quantitative assay 450 l aliquots of tested sample lysate (10 7 cells per ml) were mixed with 50 l of different concentrations of a serially diluted competitor lysate (10 7 cells per ml). The quantification of an unknown sample of a patient tested for the first time was performed in 5-7 tubes with competitor concentrations spanning the first or second PCR depending on the positivity found by qualitative PCR. The quantification of a sample of a frequent tested patient was usually performed in 3-5 tubes with competitor concentration equal to or only little different from the last test. If the patient's sample contained the b3a2 fusion gene, the b2a2 competitor was used and vice versa (Figure 1 ). The following sample treatment (RNA isolation, RT, PCR) was the same as in the qualitative assay. The products obtained by PCR amplification were separated by electrophoresis on 2% agarose -1:1 NuSieve (FMC-BioProducts, Rockland, ME, USA) and NA agarose (Pharmacia) with ethidium bromide both in gel and electrophoretic buffer, then visualized in UV light and photographed on polaroid film (Polaroid 665 or 667, St Albans, UK) or thermopaper (K65HM Mitsubishi, Tokyo, Japan). For clinical purposes, when the kinetics of the disease is followed, the visual assessment of the point of equivalence, which reflects the equivalent concentrations of the competitor and the sample, is often sufficient (Figure 2a) . For the precise estimation of the point of equivalence, band intensities were measured by densitometric analysis using the imager system from UVP (Cambridge, UK), consisting of a charge-coupled video camera connected to a Macintosh computer (Apple Computer, Cupertino, CA, USA). Image analysis was performed with GelBase/GelBlot image system (SW5100W, UVP Ltd). The intensity of the target (sample) band was corrected for target and competitor template size difference (factor 1.30 or 1.44 for K562 competitor and 0.77 or 0.69 for BV173 competitor in the first or second PCR, respectively) and for the target dilution during target and competitor mixing (factor 1.11). The point of equivalence can be estimated from the line obtained from the plot of log(T n /C n ) vs log(C 0 ) as the point where log(T n /C n ) = 0, ie T n = C n ( Figure 2b ). T n and C n express the amount of target and competitor given by intensities of bands, respectively, after n amplification cycles, C 0 expresses the initial amount of competitor cells. Figure 2b shows the difference between the
Figure 1
Diagram of the two CML typical forms of the BCR/ABL fusion gene cDNA used as natural competitors in Q-RT-PCR.̈, external and internal primers located on the BCR/ABL gene; ୴, primers located on the ABL serving as a control gene.
Figure 2
Competitive Q-RT-PCR with K562 competitor: test for linearity and estimation of the precise point of equivalence. Different concentrations of serially diluted K562 competitor lysate (C 0 ) were added to fixed amounts of patient sample lysate (T 0 ). After RNA isolation, reverse transcription and 35 cycles of PCR amplification, bands were detected on agarose gel stained with ethidium bromide (a) (visually assessed point of equivalence denoted by arrow), and quantified by the GelBase program. Log(T n /C n ) was plotted against log(C 0 ) (b). T n and C n were expressed as band intensities, C 0 as the number of leukemic cells in 10 6 leukocytes. A straight line with gradient −1.013 (r = 0.995) was yielded by linear regression analysis. Correction factors for template length difference and sample dilution during test were (˾) or were not (२) used. The dotted lines show the points of equivalence.
points of equivalence whether the correction factors are used or not.
Mathematical model of competitive PCR
The exponential accumulation of target and competitor PCR products is described by equations:
where n is number of cycles, T n target concentration after n cycles, C n competitor concentration after n cycles, T 0 initial target concentration, C 0 initial competitor concentration, E T efficiency of target amplification, E c efficiency of competitor amplification.
The ratio of Equations 1 and 2 in a linear form (equation 3) and a log form (equations 4, 5) provides a useful tool for evaluation of the competitive PCR assay.
If fixed amounts of target (T 0 ) and competitor (C 0 ) are mixed and co-amplified for different numbers of cycles (n) and log (T n /C n ) is plotted as a function of n (equation 4) a straight line with the gradient log[(1 + E T )/(1 + E C )] and intercept log(T 0 /C 0 ) is obtained. If a basic assumption for absolute quantification, E T = E C , is fulfilled the gradient equals zero and equation 4 is simplified: log(T n /C n ) = log(T 0 /C 0 ) (6) In this case the ratio of initial target and competitor amounts is maintained throughout all PCR cycles tested. If a constant amount of target (T 0 ) is mixed with different amounts of competitor (C 0 ) and co-amplified for a fixed number of cycles, plotting log(T n /C n ) as a function of log(C 0 ), a straight line with gradient −1 should be obtained even in the case of E T E C (but the ratio of E T to E C is constant) (equation 5). If E T = E C a straight line with gradient −1 and intercept T 0 is obtained.
Results
Assay reliability Stability of target/competitor ratio during PCR amplification:
The principal requirement that must be fulfilled to obtain reliable quantitative information by competitive PCR is that the competitor and target sequences should be amplified with equal efficiencies (E T = E C ) during all PCR cycles. This guarantees that the initial ratio of target and competitor remains constant throughout the amplification (T 0 /C 0 = T n /C n ). If we want to detect bands at the plateau phase, E T must equal E C in both nonexponential and plateau phase, too.
To verify this we tested the ratios of b3a2 and b2a2 coamplifying templates during various cycle numbers of both steps of two-step PCR. Although these two templates are alternatively found as target or competitor in our assay we denoted b3a2 as target (T) and b2a2 as competitor (C) to be able to make a simple comparison with the mathematical model. The reactions were terminated after various cycle numbers ranging from 20 to 35 in the first PCR, then band intensities in gel were measured by the GelBase program and the ratios calculated. The amplification products after 20, 25, 30 and 35 cycles of the first PCR were subjected to the second PCR. The reactions were again terminated after various numbers of cycles ranging from 5 to 35 and the ratios of band intensities were determined. A plot of log(T n /C n ) as a function of amplification cycle number provided straight lines with gradients near 0 ( Figure 3 , Table 1 ). According to equation 4 it confirms a very close similarity of target and competitor amplification efficiencies. However, due to the permanent positivity of the gradients it seems that the b3a2 templates, at variance with their length, are produced a little preferentially under the conditions of our PCR. No significant changes in the T n /C n ratio during the late PCR phases were found, therefore all our Q-RT-PCR assays were terminated after 35 cycles of the first PCR or, if necessary, after the following 35 cycles of the second PCR.
As the gradient of the line in the plot of log(T n /C n ) vs n equals log[(1 + E T )/(1 + E C )], according to equation 4, it is possible to calculate the ratio (1 + E T )/(1 + E C ) and according to equation 3 to find differences between T n /C n and T 0 /C 0 after n cycles as a consequence of differing amplification efficiencies ( Table 1 ). The table shows that small deviations of gradients from 0 bring increasing changes in (T n /C n )/(T 0 /C 0 ) ratio with increasing cycle number. This is further strengthened by the T/C ratio during PCR amplification. The b3a2 (T) and b2a2 (C) templates were co-amplified for 35 cycles of the 1st PCR, then the amplification products were subjected to the 2nd PCR. The reaction was terminated at various cycles ranging from 5 to 35. Band intensities were estimated by the GelBase program and log(T n /C n ) was plotted vs cycle number (n). Regression analysis was performed and the gradient was estimated (gradient = 0.00299). subsequent second PCR. In our case, even the maximal value found for two-step PCR does not exceed the value of one dilution step of the competitor extremely. The experiments testing the accuracy of our Q-RT-PCR (Figure 4 ) confirm still much closer similarity, rather identity, of the target and competitor efficiencies.
The second PCRs were started after termination of various amplification cycles of the first PCR and so the initial amount of target and competitor DNA entering the second PCR increased with the increasing cycle number of the first PCR from which they were withdrawn. We wanted to know if an initial amount of DNA influenced the gradient value or the linearity. This was not confirmed.
Linearity test:
According to equation 5 a plot of log(T n /C n ) as a function of log(C 0 ) should provide a straight line with gradient of −1 when fixed amounts of target (T 0 ) are mixed with different amounts of serially diluted competitor (C 0 ) and co-amplified for a fixed number of cycles.
We performed this test for both b3a2 and b2a2 competitors by quantification of patient samples. To obtain more points for the curve, intermediary competitor dilutions were added within the primary serial dilutions. Every concentration of the competitor was further diluted two times. Linearity and a gradient near −1 were demonstrated in both cases. A gradient of −1.013, r = 0.995 ( Figure 2b ) and a gradient of −0.909, r = 0.993 were found for the b3a2 (K562) and b2a2 (BV173) competitors, respectively (r represents the correlation coefficient). In all our experiments the linearity was confirmed with gradients varying from −0.899 to −1.225.
Assay sensitivity:
Lysates of competitor cells K562 and BV173 (10 7 cells/ml) were serially diluted with normal volunteer cell lysates (10 7 cells/ml). The one-step PCR could detect a PCR positivity of K562 or BV173 cells in dilution 10 , respectively, the two-step PCR in dilution 10 −6 -10
and 10 −6 , respectively. This high sensitivity is due to the overproduction of the BCR/ABL mRNA in these leukemic line cells. The positivity of a patient with 100% of Ph chromosome Table 1 Changes of T/C during PCR amplification as a consequence of E T and E C differences
PCR
Bands visible Gradient The b3a2 (T) and b2a2 (C) templates were co-amplified for 20 to 35 cycles during the 1st PCR and the ratio of T n /C n band intensities was determined. Then amplification products after 20, 25, 30 and 35 ( Figure 3 ) cycles were 100 times diluted, the second PCR was performed and the T n /C n intensity ratios were again estimated in various cycles ranging from 5 to 35. Log(T n /C n ) was plotted as a function of the cycle number (n), regression analysis was made and gradients determined. could be detected in a dilution of 10 −3 by the single-step PCR and 10 −5 by the two-step PCR.
Stability of competitors:
The competitors stored as cell GTC lysates at −20°C are stable for a very long time. We have been using them for more than 2 years without detecting any change in their quality. Every 3 months the competitors have been tested for sensitivity and quantified with standard samples. In routine quantification every quantified sample is accompanied by a control verifying the stability of competitors. The control included the previously quantified sample but with only two competitor concentrations, the nearest to the point of equivalence.
Assay reproducibility:
Two samples, one with the b2a2 and the other with b3a2 fusion gene, were quantified by serially diluted competitors in three parallel runs. Both samples in all three parallel runs showed visually the point of equivalence at the same competitor concentration (data not shown). Besides, a sample with b2a2 rearrangement was mixed with one competitor concentration in 10 replicas and after RNA isolation, RT and PCR, the bands in the gel were densitometrically analyzed by the GelBase program, ratios of bands calculated and statistically evaluated. Coefficient of variation (CV) was found to be 13.3%.
Overproduction of the BCR/ABL transcript in cell lines K562 and BV173 and accuracy of competitive RT-PCR
Cell line K562 is known either to produce additional Ph chromosomes or multiply the BCR/ABL gene, [26] [27] [28] [29] [30] which must appear with an increased amount of the BCR/ABL transcript. As we use cells of this line as competitors, we measured the overproduction of BCR/ABL transcript in K562. The BV173 cell line used in our laboratory was tested in the same way.
Four patients at CML diagnosis with 100% of Ph chromosome (found cytogenetically and by quantitative RT-PCR comparing the amount of BCR/ABL and BCR transcript 31 ), two of them with the b2a2 and two others with b3a2 fusion gene, were taken as standards. Cell lysates of b2a2 standards were diluted by normal cell lysate 2, 10, 20, 100, 200, 2000 and 20000-fold. All these samples were quantified in parallels using serially diluted competitor K562. The same quantification was performed with the competitor BV173. The standard lysates with the b3a2 fusion gene were diluted 20, 100, 200, 2000 and 20000-fold. The points of equivalence were determined precisely by measuring band intensities by the GelBase software including correction factors for template length difference and sample dilution. The overproduction of the competitor BCR/ABL transcript was expressed by the ratio of the competitor dilution to standard dilution at the point of equivalence. The result value of overproduction is the average of all measurements. It was found to be 82-fold and 14-fold in K562 and BV173 cell lines used in our laboratory, respectively. Figure 4 shows the differences between the expected values and found values of competitor dilution. These differences express the log of the overproduction value. The parallelism of found-value lines with the expected-value line (gradient = 1.007 and 1.013, r = 0.998 and 0.996 for K562 and BV 173, respectively) prove the accuracy of the competitive RT-PCR for both competitors in a wide range of concentrations.
Quantitative analysis of clinical samples
In this study, 30 CML patients after BMT were followed up by qualitative RT-PCR for more than a year at regular time intervals as recommended by EICML. 20 Eight of them became permanently positive and were tested by our quantitative RT-PCR technique. In all cases, samples of peripheral blood were analyzed. The disease intensity was expressed as the number of leukemic cells in 10 6 leukocytes. This value may not reflect the absolute number of leukemic cells in all instances but it permits an indication of BCR/ABL expression level to which clinicians can easily relate. The points of equivalence were estimated from lines obtained by plotting log(T n /C n ) vs log(C 0 ) ( Figure 5 -points) or assessed only visually from the band intensities on the gel (Figure 5 -lines) . In both cases, the number of leukemic cells was corrected for competitor and target template length differences, dilution of sample during target and competitor mixing and for overproduction of BCR/ABL transcript in competitor cells. The variations of the precisely estimated values and visually assessed ones are almost negligible. For this reason, a visual assessment of the points of The band intensities were estimated using the GelBase software and the points of equivalence were precisely calculated using correction factors. Log of expected (dotted line) and found competitor dilution (२ K562; ˾, BV173) at the point of equivalence were plotted vs log of standard dilution. The resulting lines can be described as follows: y = 1.007x + 1.897, r = 0.998 for K562 and y = 1.013x + 1.109, r = 0.996 for BV173.
equivalencies is sufficient when following the dynamics of the disease.
Two of the eight positive patients relapsed into blast crisis and died (retrospective study) (Figure 5a ), six of them (prospective study) relapsed molecularly or molecularly and cytogenetically but, after treatment, they became RT-PCR negative. In two of these six cases, there was a long period of a stable number of leukemic cells before further increase (Figure 5c ), in four others there was a continuous increase of leukemic cell number (Figure 5b ). One exemplary case was chosen from each of these three groups (Figure 5a, b, c) .
In all cases except two, where treatment was started before cytogenetic relapse was detected, the increase in the BCR/ABL transcript amount preceded the other signs of the disease progression. In both retrospectively tested patients time span between the increase of BCR/ABL transcript and blast crises was 7 months. In three other cases the increase of BCR/ABL was observed 2-5 months prior to a cytogenetic relapse, in one patient with a long period of stable level of BCR/ABL transcript, the first increase was found 21 months and the second increase 3 months before cytogenetic relapse. After application of therapy in molecular or cytogenetic relapse a continual decrease of BCR/ABL transcript amount under the level of two-step RT-PCR sensitivity was found in all cases. However, in all these cases further occasional positivities and one successfully treated molecular relapse were found. The dynamics of the disease is shown in Figure 5 .
Discussion
To monitor the evolution of remaining or recurrent minimal disease in CML patients after BMT we introduced a competitive RT-PCR assay. We searched for a simple, reliable, sensitive and inexpensive method with a simply preparable and stable competitor whose concentration would be easy to determine. The stability of the competitor and the sample and the possibility of a precise estimation of the initial competitor and sample concentration (C 0 , T 0 ) is very important for the accuracy and reproducibility of the assay.
The competitive method of Lion, 17, 18 where natural cDNA competitors from cell lines K562 and BV173 were used, seemed to be the most convenient for our purposes. However, we were not able to find a suitable method for the precise determination of the cDNA concentration in the mixture after reverse transcription (RT). The commonly used ethidium bromide assay 32 is not reliable because of variable amounts of ethidium bromide binding substances, above all, variable amounts of a contaminating genomic DNA in samples, especially when the acid phenol extraction method 21 is used for RNA preparation. For this reason, UV spectrophotometry also cannot be used. This problem is not solved even by mixing the competitor and the sample in RNA form. RNA is highly susceptible to degradation and UV spectrophotometry can find neither the amount of degraded RNA nor the amount of contaminating genomic DNA. A parallel competitive PCR for a control gene using artificial DNA competitor obviates the necessity of estimation of cDNA or RNA concentration. In CML the fusion BCR/ABL gene is tested in parallel with a control ABL gene and the amount of BCR/ABL transcript is related to the total mount of ABL transcript. 19, 33, 34 However, as the tested ABL fragment is present not only in the normal ABL gene but also in the BCR/ABL fusion gene, some objection can be raised.
To avoid the measuring of cDNA or RNA concentration we decided to mix the competitor and the sample as cell lysates, ie we used the competitor in an unpurified RNA form stabilized in GTC lysate. We shifted the estimation of the initial competitor and tested sample concentrations from the measuring of cDNA or RNA concentration to the estimation of cell count. The microscopical count of the cells is a simple and reliable method and at the same time it is possible to check the quality of the isolated cells. The lysates with 10 7 cells per ml are not viscious and they are very easy to handle. This method works with relatively large volumes during competitor dilution (ml) and competitor and sample mixing (450 and 50 l) and these procedures are thus subject to a smaller error than other methods working with much smaller volumes. As cell lysates instead of pure RNA or cDNA are mixed in our method it is not necessary to test either the quality and quantity of RNA or the efficiency of RT. Both competitor and sam-ple templates are influenced in the same way throughout the procedure from RNA isolation to PCR assay. This was proved by many tests. The only objection which can be raised, is the necessity of multiple (about 5) RNA isolations. Nevertheless, a shortening of RNA isolation brings minimization of laboriousness. To prevent deterioration of the quality of blood samples they should be processed and lysed in GTC as soon as possible. The high stability of GTC lysates even at room temperature should be used for shipping quality samples between distant laboratories.
As C 0 is expressed by the concentration of the BCR/ABLpositive competitor cells, the intensity of the residual disease is expressed as the number of leukemic cells per 10 6 leukocytes. This expression is very illustrative for follow-up of the disease dynamics. However, we must keep in mind that this is only a simplification because it is the amount of BCR/ABL transcript that is measured by Q-RT-PCR. We only presume that the amount of the BCR/ABL mRNA in a sample is linearly proportional to the number of leukemic cells. It may but may not be true. Precisely, the results of quantification should be expressed by the number of the BCR/ABL transcript units per 10 6 leukocytes. This unit represents the number of BCR/ABL transcripts in an idealized leukemic cell, ie number of transcripts in a leukemic cell of a 100% Ph-positive patient at the stage of CML diagnosis.
The reliability of the quantitative assay should be verified by comparing the results with the mathematical model of competitive RT-PCR. Plotting log(T n /C n ) vs log(C 0 ) should yield a straight line with a gradient of −1, according to equation 5. The mathematical model of the competitive reaction was thoroughly studied by Raeymaekers 35 who concluded that '...if a PCR assay yields a graph which is not linear or does not have a slope of −1, it can be used neither for absolute nor for relative quantification.' In some papers where linearity was tested the gradient was found to be much lower than −1. For instance, Cross 36 presented a line with gradient −0.59. We found that the decrease of the gradient value may be caused by the methods of PCR product detection and quantification rather than the unreliability of PCR assay itself. In our experiments the gradients were near −1, but only omission of background subtraction during image densitometry analysis lowered them to −0.6 and (−0.4) without influencing the point of equivalence. The densitometry image analysis methodology may be a source of many variations. 37 For precise quantification every step (baseline correction, peak evaluation, linearity, etc) should be verified and standardized, and so should the electrophoresis. However, as we evaluate the ratio of bands, the point of equivalence, where the ratio of competitor to target is 1, is not influenced. The errors of T n /C n estimation
Figure 5
Quantitative monitoring of residual disease in patients with CML after BMT. Three exemplary patients were tested by Q-RT-PCR at various time invervals after BMT. The intensity of the disease was expressed as the number of leukemic cells in 10 6 leukocytes. The points of equivalence were assessed visually as identical competitor and sample band intensities in gel (full lines) or precisely estimated by the GelBase analysis (points). (a), retrospective study; (b, c), prospective study; ↑, commencement of treatment; ↓, discontinuation of treatment; CsA, cyclosporin A; IFN, interferon ␣; CT, chemotherapy; DLI, donor leukocyte infusion. (a) The patient who was tested retrospectively, was found to become positive at 1 year after BMT with 10 3 leukemic cells in 10 6 leukocytes. During 5 months the number of leukemic cells increased 10-fold and during a further 2 months it increased 400-fold. More than 100% of leukemic cells found can probably be explained by the overproduction of BCR/ABL transcript. The patient relapsed into blast crisis and, in spite of commencement of therapy, died shortly thereafter. (b) The patient was followed-up prospectively. The first PCR analysis was made at 4 months after BMT and the patient was found to be positive with 10 3 leukemic cells in 10 6 leukocytes. During the next 2 months the positivity increased 50-fold, which was classified, according to Lion, 30, 39 as a molecular relapse. A cytogenetic relapse was also reported. The discontinuation of cyclosporin A treatment and commencement of IFN treatment gradually decreased the amount of positive cells under the two-step PCR detectable level during 5 months. After 7 months the IFN treatment was discontinued due to side-effects. The patient remained PCR negative with an incidental positivity on the level of two-step PCR sensitivity. At 25 months after BMT the positivity increased to 3 × 10 increase with increasing difference between the competitor and the sample concentration and they are situated mirrorlike around the point of equivalence, where they are the smallest. The linearity and the point of equivalence are retained but the gradient of the line is influenced.
Another problem is oversaturation of some bands with DNA. In systems where the competitor concentration differs greatly from the point-of-equivalence concentration an oversaturation of the stronger band may be found. It cannot be improved by diluting the sample before its loading on gel because the weaker band disappears by the dilution. Precise values are only in the close proximity of the point of equivalence.
According to Raeymaekers, 35 and as is evident from equation 5, the gradient −1 is not a sufficient condition for the amplification efficiencies being the same for T and C. If E T E c but the ratio of E T to E C is constant during PCR cycles the straight line with the gradient −1 is also obtained. Only the intercept of this line is changed and a line parallel with the correct line is found. However, this influences the value of the point of equivalence and spurious results are obtained. As gradient −1 is not a sufficient condition for competitive PCR assay verification, and its value is easy influenced by the methods of detection and quantification of PCR products, we do not recommend it as a proof of assay reliability. The main prerequisite of precise quantification, the stability of T 0 /C 0 ratio throughout all amplification cycles, resulting from the equivalence of E T and E C must be verified. According to the mathematical model (equation 4) a plot of log(T n /C n ) as a function of amplification cycle number gives a straight line with gradient equivalent to zero, ie parallel with the x axis, in the case of identical amplification efficiencies. If the gradient differs from zero there is a preferential accumulation of one of the PCR products. Table 2 , with theoretical calculations according to equation 4, shows that even very small gradient deviations from zero make for large differences in (T n /C n )/(T 0 /C 0 ) after one-step PCR including 35 amplification cycles. As the gradient values are very small they are probably influenced by error of measurement. For this reason, we consider the repeated quantification of the same sample in different dilutions ranging over several orders of magnitude as the most precise test of reliability and accuracy of the assay. If the point of equivalence is always found at the predicted competitor concentrations, the reliability of the assay is proved, ie E T equals E c in the tested range of dilution. We found an excellent agreement between the predicted and experimental values for sample dilution ranging from 2 to 2 × 10 4 ( Figure 4 ). The accuracy of our competitive assay checked by this approach was found to be much higher than that obtained by Table 2 Theoretical values of gradients Gradients were calculated from the relation: log(T n /C n )/(T 0 /C 0 ) = n log(1 + E T )/(1 + E C ) where log(1 + E T )/(1 + E C ) = gradient, PCR includes 35 cycles.
estimation of gradients of lines produced by plot of log(T n /C n ) vs cycle number (Table 1) . The method was found to be reproducible with the coefficient of variance 13.3%. It indicates the high reproducibility of the assay since the usual aim of competitive PCR is to quantify BCR/ABL in a range of half an order of magnitude or one dilution step of competitor. The molecular relapse is reported when 10 times increase of the BCR/ABL amount is found. 20, 39 The main source of variability is the method of densitometry image analysis. The more precise method of capillary electrophoresis is sometimes used. 38 Cell line K562 was reported to contain some additional Ph chromosome and multiple BCR/ABL genes [26] [27] [28] [29] [30] which may result in overproduction of the BCR/ABL transcript. As we used this cell line as a competitor in our competitive PCR we quantified this overproduction to obtain correct results of our assay. The production of BCR/ABL transcript in our cell line K562 was 82-fold higher in comparison with the 100% Phpositive standard. In our other competitor BV173 the overproduction was found to be 14-fold higher than in the standard. Wu et al 30 reported a 22-to 24-fold amplification of the BCR/ABL gene in K562. Our results indicate that not only amplification of the fusion gene or an additional Ph chromosome but probably also overexpression of the BCR/ABL gene appears in these cell lines. Cell line K562 is often used to estimate PCR sensitivity. If this overproduction of the BCR/ABL transcript is not taken into account the sensitivity can be strongly overrated. Correction factors characterizing overproduction of the BCR/ABL transcript, which were found in our laboratory, cannot be generally used because of a great variability of cell lines. This variability manifests itself even during repeated cultivations. K562 and BV173 cells recently cultivated in our laboratory showed further increased overproduction of BCR/ABL transcripts. These results are in accordance with the results of Wu et al, 30 who also reported an increasing amplification of the fusion gene over time.
We have applied Q-RT-PCR to the monitoring of residual disease in eight patients with CML who became positive after BMT. When the disease dynamics is followed up, a visual assessment of points of equivalence from band intensities is sensitive enough (Figures 2, 5 ), but correction factors, especially the overproduction of BCR/ABL transcript in competitor cells, must be taken into account if real values of cell count are to be assessed. In this study, we have shown that the increase of the BCR/ABL transcript amount signals that disease progression and precedes all other signs of this progression. The cytogenetic relapse was preceded by a median time span of 3.5 months. These data are in accordance with data published by other authors. 15, 16, 17, 18, 39 The in time treatment was in all cases followed by a decrease of the BCR/ABL transcript amount under the level of two-step PCR sensitivity. However, in all these cases further occasional positivities and one successfully treated molecular relapse were found. In agreement with other authors we can conclude: (1) increase of BCR/ABL transcript amount (number of leukemic cells) signals progression of the disease; (2) quantitative tests of positive patients should be performed at intervals shorter than a month because the increase of leukemic cells can be very abrupt; and (3) the disease treatment must start in time to be successful.
In conclusion, our modification of competitive Q-RT-PCR assay was proved to fulfill all criteria of competitive PCR: the amplification efficiencies of the target and competitor seem to be nearly identical; competitors stored as lysates are stable over a long time period; determination of initial competitor and sample concentration is precise and easy; mixing competitors and samples prior to RNA isolation makes possible a control for RNA extraction variability and reverse transcription efficiency; and the assay is accurate and reproducible. In addition, the method is very simple which predetermines it for clinical purposes.
